Abstract:Hyperuricemia has become a common metabolic disease, and is a risk factor for multiple diseases, including chronic kidney disease. Our recent study indicated that following persistent uric acid stimulation, autophagy was activated in rats of hyperuricemic nephropathy (HN) and facilitated the development of renal fibrosis. Nevertheless, the potential mechanism by which autophagy promoted the progression of HN is still not fully elucidated. Thus, in the current study, we investigated the mechanisms of autophagy inhibition on the development of HN. Our data showed that autophagy was activated in human renal tubular cell lines (HK-2) exposure to uric acid. Inhibition of autophagy with 3-methyladenine (3-MA) and transfected with Beclin-1 siRNA prevented uric acid-induced upregulation of α-SMA, Collagen I and Collagen III in HK-2 cells. Moreover, uric acid upregulated autophagy via promoting the p53 pathway. In vivo, we showed that hyperuricemic injury induced the activation of NLRP3 inflammasome and pyroptosis, as evidenced by cleavage of caspase-1 and caspase-11, activation of gasdermin D (GSDMD) and the release of IL-1β and IL-18. Treatment with autophagy inhibitor 3-MA alleviated aforementioned phenomenon. Stimulation with uric acid in HK-2 cells also resulted in NLRP3 inflammasome activation and pyroptotic cell death, however treatment with 3-MA prevented all these responses. Mechanistically, we showed that the elevation of autophagy and degradation of autophagolysosomes resulted in the release of cathepsin B (CTSB), which is related to the activation of NLRP3 inflammasome. CTSB siRNA can inhibit the activation of NLRP3 inflammasome and pyroptosis. Collectively, our results indicate that autophagy inhibition protects against HN through inhibiting NLRP3 inflammasome-mediated pyroptosis. What's more, blockade the release of CTSB plays a crucial role in this process. Thus, inhibition of autophagy may be a promising therapeutic strategy for hyperuricemic nephropathy.

The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy

Targeting Toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy

Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease

Chronic kidney disease and NLRP3 inflammasome: Pathogenesis, development and targeted therapeutic strategies

Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy

NLRP3 Inflammasome: A central player in renal pathologies and nephropathy

Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis

The role of uric acid in inflammasome-mediated kidney injury

The Inhibitor Effect of RKIP on Inflammasome Activation and Inflammasome-Dependent Diseases

Su1795 Uric Acid Regulates Hepatic Steatosis and Insulin Resistance Through the NLRP3 Inflammasome Dependent Mechanism

Role of Inflammasomes in Kidney Diseases via Both Canonical and Non-canonical Pathways

The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy

Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency

Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases

Research Progress on the Role of Inflammasomes in Kidney Disease

The Role of NLRP3 Inflammasome in IgA Nephropathy

Pathophysiological role and potential drug target of NLRP3 inflammasome in the metabolic disorders

Targeting the NLRP3 Inflammasome in Diabetic Nephropathy

[Molecular Regulative Mechanisms of NLRP3 Inflammasome Activation in Diabetic Nephropathy and Interventional Effects of Chinese Herbal Medicine].

The NLRP3 inflammasome in kidney disease and autoimmunity

NLRP3 Inflammasome in Metabolic-Associated Kidney Diseases: An Update